Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes

Dermatol Ther. 2016 Nov;29(6):451-454. doi: 10.1111/dth.12391. Epub 2016 Jul 18.

Abstract

Acne vulgaris is a multifactorial skin disease associated with the colonization of Propionibacterium acnes. Antibiotics are a mainstay of treatment for acne, yet the emergence of resistance against the currently approved antibiotics is a serious concern. In this case report, a slow responder had multiple Propionibacterium acnes isolates with varied levels of sensitivity to the conventional antibiotics. The bacterial isolates obtained from acne samples collected from the patient were analyzed for phylogeny, and was found to be largely restricted to two different lineage patterns. Propionibacterium acnes phylotype IA1, which is considered to be pathogenic, displayed clindamycin sensitivity, but phylotype IB, which is associated with commensals, exhibited high clindamycin resistance. Sensitivity analysis revealed uniform resistance to macrolides, but susceptibility to tetracycline and nadifloxacin. These results implicate Propionibacterium acnes in the pathophysiology of acne vulgaris, although the lines between commensal and pathological phylotypes may be blurred. Switching the patient to a combination of minocycline and nadifloxacin resulted in a significant improvement in the clinical lesions. Such a science-driven judicious selection of antibiotics can minimize the probability of development of resistance, and might be the way forward in the treatment of acne.

Keywords: Propionibacterium acnes; antibiotic resistance; clindamycin; commensal; phylotype.

Publication types

  • Case Reports

MeSH terms

  • Acne Vulgaris / diagnosis
  • Acne Vulgaris / drug therapy*
  • Acne Vulgaris / microbiology
  • Anti-Bacterial Agents / therapeutic use*
  • Drug Resistance, Bacterial*
  • Drug Substitution*
  • Drug Therapy, Combination
  • Fluoroquinolones / therapeutic use*
  • Genotype
  • Humans
  • Male
  • Minocycline / therapeutic use*
  • Phenotype
  • Phylogeny
  • Propionibacterium acnes / classification
  • Propionibacterium acnes / drug effects*
  • Propionibacterium acnes / genetics
  • Propionibacterium acnes / pathogenicity
  • Quinolizines / therapeutic use*
  • Remission Induction
  • Ribotyping
  • Skin / drug effects*
  • Skin / microbiology
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • Quinolizines
  • nadifloxacin
  • Minocycline